A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. METHODS: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. RESULTS: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died. CONCLUSIONS: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.138–140”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [139]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Research works printed but not linked: 1
- Sullivan KM, 1991, Semin Hematol, 28, 250
Cited by
Items 301–400 of 503
Gerull, S., Stern, M., Aïssa, A. B., Manz, M. G., Schanz, U., Stüssi, G., Chalandon, Y., Passweg, J. R., & Mohty, B. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.167 · Cited by 6
Rabin, N. K., Percy, L. A., Khan, I., Quinn, J., D’Sa, S., & Yong, K. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09188.x · Cited by 7
“The use of tandem autologous stem cell transplantation (ASCT) protocols has been explored in several studies, but the benefit, if any, of double ASCT is confined to patients who fail to achieve high quality responses following the first HDT (Attal et al, 2003; Cavo et al, 2007).”
BackgroundMunker, R., Lazarus, H. M., & Atkinson, K. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511575525 · Cited by 8
Kawamura, K. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03602-1 · Cited by 6
Wei, M., Xie, C., Huang, J., Liu, Q., & Lai, Y. (2023) · Hematology · doi:10.1080/16078454.2023.2269509 · Cited by 7
“The potential superiority of auto-allo-SCT was suggested by Bruno et al. [33,34].”
BackgroundGiaccone, L., Brunello, L., Festuccia, M. B., Gilestro, M., Maffini, E., Ferrando, F., Talamo, E., Passera, R., Boccadoro, M., Omedè, P., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.319 · Cited by 6
Self-citationMinnema, M. C., van Dorp, S., van de Donk, N. W. C. J., Schouten, F., Kersten, M. J., Coenen, J. L., Schouten, H. C., Zweegman, S., Schaafsma, R., & Lokhorst, H. M. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.101 · Cited by 7
Nair, A. P., Walker, P., Kalff, A., Bergin, K., Hocking, J. S., Avery, S., Curtis, D. J., Patil, S., Das, T., Klarica, D., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.37 · Cited by 7
Gołoś, A., Gil, L., Puła, B., Boguradzki, P., Hałaburda, K., Sawicki, W., Sobczyk‐Kruszelnicka, M., Helbig, G., Dybko, J., Jurczyszyn, A. J., et al. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.08.003 · Cited by 6
Jürgensen-Rauch, A., Gibbs, S., Farrell, M., Aries, J. A., Grantham, M., Eccersley, L., Gribben, J. G., Hallam, S. L., Oakervee, H. E., Cavenagh, J. D., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17379 · Cited by 7
Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Claveau, J., Buadi, F. K., & Kumar, S. K. (2022) · Oncology and Therapy · doi:10.1007/s40487-022-00195-3 · Cited by 7
“The standard graft-versus-host prophylaxis used in Hovon-50 [62], Italian study [26], BMT CTN [30], and NMAM2000 [28] is cyclosporine in combination with mycophenolate mofetil.”
BackgroundAllogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma
Danylesko, I., Shimoni, A., & Nagler, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.021 · Cited by 6
Bone marrow transplant and pediatric multiple myeloma
Davidow, K. A., Walter, A. W., & Kolb, E. A. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27528 · Cited by 6
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation
Bensinger, W. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0027-z · Cited by 6
Porter, D., Hexner, E. O., Cooley, S., & Miller, J. S. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_20 · Cited by 6
Diagnosis and Treatment of Multiple Myeloma
Rajkumar, S. V., & Kyle, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_33 · Cited by 6
Allogeneic Transplantation in Multiple Myeloma
Gahrton, G. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_12 · Cited by 5
Kröger, N. M., Wulf, G. G., Hegenbart, U., Burchert, A., Stelljes, M., Gagelmann, N., Brecht, A., Kaufmann, M., Müller, L. P., Ganser, A., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.282920 · Cited by 5
“9,12 A recently published analysis with individual patients’ data from four of these trials showed a significantly improved progression-free survival (PFS) as well as OS after alloTSCT after a median follow-up of 10 years.”
Jamshed, S., Fowler, D. H., Neelapu, S. S., Dean, R. M., Steinberg, S. M., Odom, J., Bryant, K., Hakim, F. T., & Bishop, M. R. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.173 · Cited by 5
Green, D. J., & Bensinger, W. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0365-2 · Cited by 5
Evolution or revolution in multiple myeloma therapy and the role of the UK
Cook, G., & Morris, C. T. C. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17148 · Cited by 7
“However a limited number of studies have now been reported showing that the benefits of allo-SCT may be obtained by combining a reduced-intensity allo-SCT with a prior ASCT (auto–allo) thus reducing the transplant-related mortality, although benefit for the auto–allo group only became obvious after five-year followup.…”
BackgroundRamasamy, K., Mahmood, S., Lim, Z., Corderoy, S., Devereux, S., Mufti, G. J., Pagliuca, A., & Schey, S. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.004 · Cited by 5
Morris, C., Iacobelli, S., Gahrton, G., van Biezen, A., Drake, M. B., Garderet, L., Potter, M. N., Schattenberg, A. V. M. B., Cornelissen, J. J., Hamladji, R., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.02.012 · Cited by 5
“As this survey covers a wide time period, it seems probable that the improved outcome measures noted in successive time cohorts [10] and confirmed in recent randomized clinical trials [11,12] could apply to the rare myelomas, but the number of cases is too small for this analysis.”
ResultRole of Immune Therapies for Myeloma
Rosenblatt, J. M., & Avigan, D. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0168 · Cited by 6
Munshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Holstein, S. A., Liu, H., & McCarthy, P. L. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.08.010 · Cited by 5
Cellular immunity in the era of modern multiple myeloma therapy
Liu, Z., Zhao, X., Shen, H., Liu, X., Xu, X., & Fu, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34609 · Cited by 5
“More than 30 years after its introduction, autologous stem cell trans- plantation (ASCT) remains the standard of care for MM patients and is recommended by the American Society of Clinical Oncology(ASCO) and European Society of Medical Oncology(ESMO).147,148 ASCT improves PFS and OS, even in high-risk and RRMM patient…”
BackgroundInfluentialThe evolving background for high-dose treatment for myeloma
Sirohi, B., Powles, R., Harousseau, J., & Anderson, K. C. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705867 · Cited by 5
Costa, L. J., Kumar, S. K., Dispenzieri, A. A., Hayman, S. E., Buadi, F. K., Dingli, D., Litzow, M. R., Gertz, M. A., & Lacy, M. Q. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902803644 · Cited by 6
“This observation triggered interest in performing sequential cytoreductive autologous transplant and a RIC allograft [11,12].”
BackgroundMethodAllografting or Autografting for Myeloma
van Rhee, F., Crowley, J. J., & Barlogie, B. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076161 · Cited by 5
Controversies in Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma
Bhatnagar, B., & Ashraf, Z. (2013) · InTech eBooks · doi:10.5772/54115 · Cited by 4
Novel Agents to Improve Outcome of Allogeneic Transplantation for Patients with Multiple Myeloma
Kortüm, K. M., Knop, S. T., & Einsele, H. (2010) · Future Oncology · doi:10.2217/fon.10.162 · Cited by 4
Management of high-risk Myeloma: an evidence-based review of treatment strategies
Lehners, N., Hayden, P. J., Goldschmidt, H., & Raab, M. S. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1204908 · Cited by 4
“Significantly superior PFS and OS were seen in those treated with alloSCT [99,100].”
Transplantation for Multiple Myeloma
Jethava, Y. S., & van Rhee, F. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_13 · Cited by 5
UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Tosi, P., Imola, M., Maria, M. A., Tomassetti, S., Merli, A., Molinari, A., Mangianti, S., Ratta, M., Isidori, A., & Visani, G. (2012) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2012.069 · Cited by 5
Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014
Landau, H. J., & Giralt, S. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.004 · Cited by 5
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
Martino, M. V., Paviglianiti, A., Gentile, M., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04142-7 · Cited by 4
Kaloyannidis, P., & Apostolidis, J. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00864-x · Cited by 4
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma
Firsova, M. V., Менделеева, Л. П., Parovichnikova, E. N., Solovev, M. V., Kuzmina, L. A., Risinskaya, N., Abramova, T. V., Galtseva, I. V., & Vg, S. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.07.200929 · Cited by 4
Lin, C., & Sung, Y. (2009) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(09)50006-4 · Cited by 4
New drugs in the therapy of multiple myeloma
Palumbo, A., & Falco, P. (2008) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842008000800005 · Cited by 4
Self-citationTaverna, C., Bargetzi, M. J., Betticher, D. C., Gmür, J., Gregor, M., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13054 · Cited by 4
Integrating Novel Therapies in the Transplant Paradigm
Harousseau, J. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c51ca3 · Cited by 4
Allogeneic Transplantation for Multiple Myeloma
Wang, F., & Waller, E. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_10 · Cited by 4
Myeloma and other Paraproteinaemias
Robert Souhami CBE, M., & Tobias, J. S. (2005) · Wiley eBooks · doi:10.1002/9780470994887.ch27 · Cited by 4
Borst, N., Ihorst, G., Wenger, S., Räder, J., Wäsch, R., Engelhardt, M. M., & Rassner, M. P. (2024) · Cancers · doi:10.3390/cancers16234090 · Cited by 4
“However, allo-SCT is performed less frequently today due to its associated toxicity, including transplant-related mortality and adverse events, such as graft-versus-host disease [29–32], as well as due to other immunotherapies being currently available.”
Reduced-Intensity and Nonmyeloablative Conditioning Regimens
Foss, F. M., & van Besien, K. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_9 · Cited by 3
“A randomized study from Italy showed a benefit of sequential autologous followed by allogeneic transplantation over double autologous transplantation in patients with myeloma in first response [110].”
BackgroundSpoerl, S., Peter, R., Wäscher, D., Verbeek, M., Menzel, H., Peschel, C., & Krackhardt, A. M. (2015) · Transfusion · doi:10.1111/trf.13206 · Cited by 3
Schmitt, S., Hielscher, T., Baldus, C. D., Neben, K., Egerer, G., Hillengaß, J., Raab, M., Hose, D., Ho, A. D., Bergner, R., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1320-1 · Cited by 3
“Five patients had undergone double autologous-allogeneic transplantation [13].”
BackgroundGomez, E., Duléry, R., Langlois, C., Coiteux, V., Terriou, L., Magro, L., Gauthier, J., de Berranger, E., Duhamel, A., & Yakoub‐Agha, I. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.193 · Cited by 3
Mactier, C. E., & Islam, M. S. (2012) · Oncology Reviews · doi:10.4081/oncol.2012.e14 · Cited by 3
Vertebra Plana in an Adolescent Caused by Multiple Myeloma
Greenleaf, R. M., Ricciardella, L. F., Latona, C. R., & Sangimino, M. J. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.00640 · Cited by 3
Mussetti, A., Salas, M. Q., & Montefusco, V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113437 · Cited by 3
Treatment options for multiple myeloma patients with high-risk disease
Ailawadhi, S., Masood, A., Sher, T., Miller, K. C., Wood, M., Lee, K. P., & Chanan-Khan, A. A. (2010) · Medical Oncology · doi:10.1007/s12032-010-9521-4 · Cited by 3
“technique, but included all comers in the analysis, irrespective of risk stratification [ 54 ].”
MethodRole of allogeneic stem cell transplantation in multiple myeloma
Kumar, S. K. (2008) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-008-0015-9 · Cited by 3
Siddiqui, M. A., & Gertz, M. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802084972 · Cited by 3
Autologous stem-cell transplantation in patients with multiple myeloma.
Stojanoski, Z., Georgievski, B., Cevreska, L. A., Stojanovic, A. T., Pivkova-Veljanovska, A., Genadieva-Stavric, S., Stankovic, S., & Karadzova-Stojanoska, A. (2008) · PubMed · Cited by 3
Managing Infections in Patients With Hematological Malignancies
Kleinberg, M. E. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-415-5 · Cited by 5
Therapie des multiplen Myeloms: Was ist gesichert?
Peest, D., Ganser, A., & Einsele, H. (2013) · Der Internist · doi:10.1007/s00108-013-3323-7 · Cited by 3
Multiple Myeloma and Plasmacytoma
Chng, W. J., & Tham, I. W. K. (2011) · Medical radiology · doi:10.1007/978-3-642-16333-3_10 · Cited by 3
Prognosis and Staging of Multiple Myeloma
Miguel, J. F. S., García‐Sánz, R., & Gutierrez, N. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_32 · Cited by 3
Recent advances in myeloma treatment
Schots, R. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.01.018 · Cited by 3
“In the Italian trial, alloSCT was superior, mostly due to a marked reduction in relapse rate [37].”
BackgroundGenetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy
Jakóbisiak, M., & Gołąb, J. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0091-0 · Cited by 3
“…cells, lower relapse rates have been observed in patients obtaining allogeneic versus syngeneic or autologous cells (Anderson et al. 1993; Bruno et al. 2007; Jones et al. 1991; Martinelli et al. 2000) and in those developing GVHD (Anderson et al. 1993; Toze et al 2005; Weiden et al.…”
BackgroundAlex, J., Erickson, Y. O., & Schlueter, A. J. (2007) · Journal of Clinical Apheresis · doi:10.1002/jca.20154 · Cited by 3
“INTRODUCTION Patients with multiple myeloma are often candidates for autologous hematopoietic progenitor cell transplantation, either as definitive treatment or in preparation for allogeneic transplantation [1,2].”
BackgroundTherapie des multiplen Myeloms: Indikationen und Möglichkeiten
Peest, D., & Ganser, A. (2007) · Der Internist · doi:10.1007/s00108-007-1959-x · Cited by 3
Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma
Moreau, P. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.365 · Cited by 2
Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Aslam, M. F., Cheema, A. Y., Shahid, D., Bibi, M., Mukhopadhyay, D., Munir, M., Najam, A., Ali, H. M., Bashir, Q., & Anwer, F. (2024) · Acta Haematologica · doi:10.1159/000542704 · Cited by 2
“In 2007, Bruno et al. [7] conducted a randomized study comparing outcomes between 80 newly diagnosed MM (NDMM) patients who underwent a combination of auto-SCT followed by allo-SCT from an HLA-identical sibling and 82 patients who received tandem auto-SCT.”
Reduced‐intensity Allogeneic Transplantation Regimens
Sandmaier, B. M., & Storb, R. F. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch21 · Cited by 2
Self-citationRajkumar, S. V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00193-7 · Cited by 4
Peng, Y., Li, Y., Lo, H. H., Law, B. Y. K., & Wong, V. K. W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_6 · Cited by 2
Pautas, C., Hicheri, Y., & Debbache, K. (2007) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(07)80397-2 · Cited by 2
Singh, A. K., Chen, J., Calado, R. T., Sowers, A. L., Mitchell, J. B., & Barrett, A. J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.121 · Cited by 2
Kang, S. H., Hwang, H. S., Park, H. S., Sun, I. O., Choi, S. R., Chung, B. H., Choi, B. S., Yang, C. W., Kim, Y., Min, C., et al. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.10.1310 · Cited by 2
Hematopoietic Cell Transplantation for Multiple Myeloma
Qazilbash, M. H., & Giralt, S. (2009) · Wiley eBooks · doi:10.1002/9781444303537.ch58 · Cited by 2
Stojanoski, Z., Georgievski, B., Oliver, K., Sonja, G.-S., Pivkova-Veljanovska, A., & Cevreska, L. A. (2013) · Serbian Journal of Experimental and Clinical Research · doi:10.5937/sjecr14-1882 · Cited by 3
Nishihori, T., Kharfan‐Dabaja, M. A., Ochoa-Bayona, J. L., Bazarbachi, A. A., Pasquini, M. C., & Alsina, M. (2011) · Hematology/Oncology and Stem Cell Therapy · doi:10.5144/1658-3876.2011.1 · Cited by 2
Primärtherapie beim Multiplen Myelom
Breitkreutz, I., Raab, M., & Goldschmidt, H. (2018) · Der Internist · doi:10.1007/s00108-018-0527-x · Cited by 3
Nguyen, P., Muirhead, J., Tan, J. L. C., Kalff, A., Bergin, K., Walker, P., & Spencer, A. G. (2022) · Internal Medicine Journal · doi:10.1111/imj.15842 · Cited by 2
Radiation Therapy in Multiple Myeloma
Greenberger, J. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_4 · Cited by 2
Tuncer, H. H., Gregory, S. A., & Fung, H. C. H. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.251 · Cited by 2
Survival from multiple myeloma in England and Wales up to 2001
Schey, S. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604608 · Cited by 2
“…allogeneic stem cell transplant in newly diagnosed myeloma has recently been compared with tandem autologous stem cell transplantation with a significant improvement in EFS and OS for the RIC allograft arm (35 vs 29 months, P¼ 0.02 and 80 vs 54 months, P¼ 0.01, respectively) (Bruno et al, 2007).”
BackgroundInfluentialThe stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?
Müller, A. M. S., Kumar, S. K., & Bruno, B. (2019) · Haematologica · doi:10.3324/haematol.2018.206987 · Cited by 2
Self-citationMyeloma and other paraproteinaemias
Tobias, J. S., & Hochhauser, D. (2014) · Wiley eBooks · doi:10.1002/9781118468753.ch27 · Cited by 2
Myeloma and other Paraproteinaemias
Tobias, J. S., & Hochhauser, D. (2009) · Wiley eBooks · doi:10.1002/9781444306361.ch27 · Cited by 2
The Current Role of Stem Cell Transplantation in Multiple Myeloma
Gupta, A. K. (2012) · InTech eBooks · doi:10.5772/33242 · Cited by 1
“[68],[69],[70] In view of these differing studies, the results of a major ongoing Bone Marrow Transplant Clinical Trial Network study are eagerly awaited.”
Richardson, T., Kobbe, G., Fenk, R. R., Schroeder, T., Crysandt, M. M., Neuerburg, C., Holderried, T. A. W., Schütte, D., Gödel, P., Hallek, M. J., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14346 · Cited by 1
“Already in 2007, Bruno et al. [12] described the outcomes of 58 patients with first-line treatment with an auto-allo concept, showing a significant advantage in OS and event-free survival compared to autologous transplantation alone; 53% of patients who received a CR had long-time PFS in an update…”
Multiple myeloma – current status and future directions
Rasche, L., & Knop, S. T. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.841577 · Cited by 1
“Clinical trials on the use of allogeneic transplant in first line have been conflicting with only two studies showing superiority of auto-followed by allografting in terms of PFS and OS [62,63].”
ResultGammapathie monoclonale et myélome multiple : quelles nouveautés ? quelles perspectives ?
Grosbois, B. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.04.009 · Cited by 2
Modern Treatment Options for Elderly Patients with Multiple Myeloma
rner, M. G. O., & th-Schwalbe, E. S. A. (2008) · Onkologie · doi:10.1159/000127403 · Cited by 1
"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"
Bruno, B., Giaccone, L., Festuccia, M. B., & Boccadoro, M. (2010) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2010.013 · Cited by 1
Self-citationThe Scope of Stem Cell Transplantation in Tissue and Organ Regeneration: Myth or Reality?
Bishi, D. K., & Guhathakurta, S. (2014) · Cited by 1
Fundamentals in the management of multiple myeloma.
Fadilah, S. A. W. (2010) · PubMed · Cited by 2
Allogeneic hematopoietic cell transplantation in multiple myeloma
Randhawa, J. K., Singh, V., & Hari, P. (2014) · Wiley eBooks · doi:10.1002/9781118589199.ch60 · Cited by 1
Allogeneic Hematopoetic Cell Transplantation in Multiple Myeloma
Topçuoğlu, P., Civriz, S., & Demirer, T. (2013) · InTech eBooks · doi:10.5772/54762 · Cited by 1
“Bruno [29] 80 vs 82 Low-dose TBI 26 vs 55 p=.”
BackgroundNK-92 Cytotoxicity Against Cancer Stem Cells in Hematologic Malignancies
Williams, B. A., Swift, B. E., Cheng, R. Y., & Keating, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-5645-8_24 · Cited by 1
4. Role of Hematopoietic Stem Cell Transplantation in the Treatment of Lymphoid Malignancies.
Kanda, Y. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.1875 · Cited by 1
Treatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 2
Davies, S. G., Kennewell, P. D., Russell, A. J., Silpa, L., Westwood, R., & Wynne, G. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12296-6 · Cited by 2
TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA
Rajkumar, S. V., & Kyle, R. A. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.003 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Metadata
- Authors
- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., & Boccadoro, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Udine (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Candiolo Cancer Institute (IT)
- University of Washington (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-15
- Volume
- 356
- Issue
- 11
- Pages
- 1110-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010766702
- Semantic Scholar
- 67383c7f6bdb3318b2667d1aad826b28d4117193
- Cited by
- 501
- References
- 35
- Citations by year
- 2025: 3 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 13 · 2018: 16 · 2017: 26 · 2016: 22 · 2015: 34 · 2014: 23 · 2013: 43 · 2012: 33
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Cancer Institute (CA 78902, P01CA078902)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, allogeneic stem cell transplantation, autologous stem cell transplantation, matched sibling donor, graft-versus-host disease, overall survival, event-free survival, complete remission, non-relapse mortality, newly diagnosed multiple myeloma
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Multiple Myeloma, Transplantation, Autologous, Transplantation, Homologous, Multivariate Analysis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.